Database : HANSEN Search on : RESISTENCIA BACTERIANA A DROGAS [Subject descriptor] References found : 3 [refine] Displaying: 1 .. 3   in format [Detailed]

page 1 de 1

1 / 3

HANSEN

select to print

Id: 17691 Author: Scollard, D. M; Adams, L. B; Gillis, T. P; Krahenbuhl, J. L; Truman, R. W; Williams, D. L Title: The continuing challenges of leprosy ..- Source: s.l; s.n; 2006. 44 p. ilus, tab. Abstract: Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases. (AU). Descriptors: Antiinfecciosos/TU Proteínas de Bactérias/ME Vacinas Bacterianas Modelos Animais de Doenças Suscetibilidade à Doença/IM Resistência Bacteriana a Drogas Genes Bacterianos/GE Predisposição Genética para Doença Genoma Bacteriano Imunidade Celular Imunidade Natural/GE Hansenostáticos/PD/TU Hanseníase/*/DI/MI/TH Mycobacterium leprae/*/CH/DE/IP/PH Nervos Periféricos/MI Doenças do Sistema Nervoso Periférico/MI/PA Reação em Cadeia da Polimerase Research Support, N.I.H., Extramural Células de Schwann/IM/MI Limits: HUMANO ANIMAL CAMUNDONGOS SUPPORT, NON-U.S. GOV'T Location: BR191.1; 09365/S

2 / 3

HANSEN

select to print

Id: 15626 Author: Ishii, Norihisa Title: Recent advances in the treatment of leprosy ..- Source: s.l; s.n; 2003. 9 p. tab. Abstract: Leprosy, a chronic infectious disease caused by Mycobacterium leprae, was identified by G. H. A. Hansen in 1873. The different clinical presentations of the disease are determined by the quality of the host immune response. The bacteria have affinity for the peripheral nerves and are likely the cause of neuropathy, a cardinal manifestation of the disease. WHO recommends a protocol of multidrug therapy (MDT), which effectively controls the disease, hence contributing to the global elimination program. Early detection of leprosy and treatment by MDT are the most important steps in preventing deformity and disability. (AU). Descriptors: COMORBILIDADE PAISES EM DESENVOLVIMENTO ESQUEMA DE MEDICACAO Resistência Bacteriana a Drogas QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/clas HANSENIASE/diag HANSENIASE/quimioter HANSENIASE/epidemiol PREVALÊNCIA Limits: HUMANO Electronic Medium: http://www.ilsl.br Location: BR191.1; 09160/s; BR191.1; 09161/s

3 / 3

HANSEN

select to print

Id: 13660 Author: Ishii, Norihisa Title: Recent advances in the treatment of leprosy ..- Source: s.l; s.n; 2003. 9 p. tab. Abstract: Leprosy, a chronic infectious disease caused by Mycobacterium leprae, was identified by G. H. A. Hansen in 1873. The different clinical presentations of the disease are determined by the quality of the host immune response. The bacteria have affinity for the peripheral nerves and are likely the cause of neuropathy, a cardinal manifestation of the disease. WHO recommends a protocol of multidrug therapy (MDT), which effectively controls the disease, hence contributing to the global elimination program. Early detection of leprosy and treatment by MDT are the most important steps in preventing deformity and disability. (AU). Descriptors: COMORBILIDADE PAISES EM DESENVOLVIMENTO ESQUEMA DE MEDICACAO HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/clas HANSENIASE/diag HANSENIASE/quimioter HANSENIASE/epidemiol Resistência Bacteriana a Drogas QUIMIOTERAPIA COMBINADA - PREVALÊNCIA Limits: HUMANO Electronic Medium: http://www.ilsl.br Location: BR191.1; 09135/s

---

page 1 de 1

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information